Table I.
Clinicopathological characteristics of patients with EEA in TCGA and PKUPH cohorts.
| TCGA cohort | PKUPH cohort | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable | Overall (n=154) | PE (n=64) | R/D-PE (n=90) | P-value | Overall (n=21) | PE (n=13) | R/D-PE (n=8) | P-value |
| Age, years | 0.09 | 0.631 | ||||||
| Median (range) | 64 (35–90) | 62 (35–89) | 65 (35–90) | 55 (31–75) | 51 (41–75) | 56 (31–63) | ||
| <60, n | 55 | 28 | 27 | 13 | 10 | 5 | ||
| ≥60, n | 99 | 36 | 63 | 8 | 3 | 3 | ||
| Grade, n | 0.005 | 0.930 | ||||||
| 1–2 | 80 | 42 | 38 | 18 | 11 | 7 | ||
| 3 | 74 | 22 | 52 | 3 | 2 | 1 | ||
| FIGO, n | 0.005 | 0.203 | ||||||
| I | 105 | 52 | 53 | 12 | 9 | 3 | ||
| II–IV | 49 | 12 | 37 | 9 | 4 | 5 | ||
| Menopause status, n | 0.789 | 0.131 | ||||||
| Premenopausal | 12 | 4 | 8 | 4 | 4 | 0 | ||
| Postmenopausal | 129 | 54 | 75 | 17 | 9 | 8 | ||
| Unknown | 13 | 6 | 7 | 0 | 0 | 0 | ||
| ER status, n | 0.133 | |||||||
| Positive | NA | 19 | 13 | 6 | ||||
| Negative | 2 | 0 | 2 | |||||
| PR status, n | 0.381 | |||||||
| Positive | NA | 20 | 13 | 7 | ||||
| Negative | 1 | 0 | 1 | |||||
| Lymph node status, n | 0.008 | 0.716 | ||||||
| Positive | 22 | 4 | 18 | 2 | 1 | 1 | ||
| Negative | 46 | 25 | 21 | 19 | 12 | 7 | ||
| Unknown | 86 | 35 | 51 | 0 | 0 | 0 | ||
| Adjuvant radiotherapy, n | <0.001 | 0.67 | ||||||
| Yes | 41 | 0 | 41 | 11 | 6 | 5 | ||
| No | 110 | 64 | 46 | 9 | 6 | 3 | ||
| Unknown | 3 | 0 | 3 | 1 | 1 | 0 | ||
| Adjuvant chemotherapy, n | 0.599 | |||||||
| Yes | NA | 13 | 7 | 6 | ||||
| No | 6 | 4 | 2 | |||||
| Unknown | 2 | 2 | 0 | |||||
| BMI, n | <0.001 | 0.659 | ||||||
| <28 | 40 | 40 | 0 | 10 | 7 | 3 | ||
| ≥28 | 108 | 24 | 84 | 11 | 6 | 5 | ||
| Unknown | 6 | 0 | 6 | 0 | 0 | 0 | ||
EEA, endometrioid endometrial adenocarcinoma; TCGA, The Cancer Genome Atlas; PKUPH, Peking University People's Hospital; PE, primary EEA samples; R/D-PE, relapsed or deceased primary EEA samples; FIGO, International Federation of Gynecology and Obstetrics; BMI, body mass index.